Chimeric proteins for treatment of acute radiation syndrome
AssigneeSilver Creek Pharmaceuticals, Inc.
InventorsLakhmir S. Chawla, Kristopher M. Kuchenbecker
Life of this patent
Estimating the term…
Abstract
Aspects of the present disclosure relate generally to chimeric proteins and pharmaceutical compositions comprising such chimeric proteins, and methods for using such chimeric proteins for treating acute radiation syndrome in subjects in thereof.
Claims26
A method of effecting radioprotection, the method comprising:
- administering a composition comprising an effective amount of a chimeric protein to provide radioprotection to a subject in need thereof,
- wherein the chimeric protein comprises a targeting domain comprising human annexin 5 or variant thereof, and an activator domain comprising insulin-like growth factor (IGF-1), neuregulin (NRG) or variant thereof, and
- wherein the composition is administered to the subject between 3 hours to 7 days prior to radiation exposure.
A method of mitigating radiation injury, the method comprising:
- administering a composition comprising an effective amount of a chimeric protein to a subject in need thereof,
- wherein the chimeric protein comprises a targeting domain comprising human annexin 5 (AnxV) or variant thereof, and an activator domain comprising insulin-like growth factor (IGF-1), neuregulin (NRG) or variant thereof, and
- wherein the composition is administered once or multiple times a day to the subject between 1 hour and 21 days after radiation exposure.
A method of effecting radioprotection and mitigating injury from radiation, the method comprising:
- administering a composition comprising an effective amount of a chimeric protein to a subject in need thereof,
- wherein the chimeric protein comprises a targeting domain comprising human annexin 5 (AnxV) or variant thereof, and an activator domain comprising insulin-like growth factor (IGF-1), neuregulin (NRG) or variant thereof,
- wherein the composition is initially administered to the subject between 3 hours to 7 days prior to radiation exposure, and
- wherein the composition is subsequently administered once a day or multiple times a day to the subject between 1 hour and 21 days after the radiation exposure.
A method of treating acute radiation syndrome (ARS), the method comprising:
- administering a composition comprising a therapeutically effective amount of a chimeric protein to a subject in need thereof,
- wherein the chimeric protein comprises a targeting domain comprising human annexin 5 (AnxV) or variant thereof, and an activator domain comprising insulin-like growth factor (IGF-1), neuregulin (NRG) or variant thereof, and
- wherein the composition is administered to the subject within 1 to 72 days after radiation exposure.
A composition for use in a method of effecting radioprotection, comprising:
- administering the composition comprising an effective amount of a chimeric protein to a subject in need thereof,
- wherein the chimeric protein comprises a targeting domain comprising human annexin 5 or variant thereof, and an activator domain comprising insulin-like growth factor (IGF-1), neuregulin (NRG) or variant thereof, and
- wherein the composition is administered to the subject between 3 hours to 7 days prior to radiation exposure.
A composition for use in a method of mitigating radiation injury, comprising:
- administering the composition comprising an effective amount of a chimeric protein to a subject in need thereof,
- wherein the chimeric protein comprises a targeting domain comprising human annexin 5 (AnxV) or variant thereof, and an activator domain comprising insulin-like growth factor (IGF-1), neuregulin (NRG) or variant thereof, and
- wherein the composition is administered once or multiple times a day to the subject between 1 hour and 21 days after radiation exposure.
A composition for use in a method of effecting radioprotection and mitigating injury from radiation, comprising:
- administering the composition comprising an effective amount of a chimeric protein to a subject in need thereof,
- wherein the chimeric protein comprises a targeting domain comprising human annexin 5 (AnxV) or variant thereof, and an activator domain comprising insulin-like growth factor (IGF-1), neuregulin (NRG) or variant thereof,
- wherein the composition is initially administered to the subject between 3 hours to 7 days prior to radiation exposure, and
- wherein the composition is subsequently administered once a day or multiple times a day to the subject between 1 hour and 21 days after the radiation exposure.
A composition in a method for treating acute radiation syndrome (ARS), comprising:
- administering the composition comprising a therapeutically effective amount of a chimeric protein to a subject in need thereof,
- wherein the chimeric protein comprises a targeting domain comprising human annexin 5 (AnxV) or variant thereof, and an activator domain comprising insulin-like growth factor (IGF-1), neuregulin (NRG) or variant thereof,
- wherein the composition is administered to the subject within 1 to 72 days after radiation exposure.
Dependencies are inferred from the claim text.